Exelixis Reports Strong Q1 2026 Results, Authorizes New $750M Share Buyback, and Zanzalintinib NDA Acceptance

summarizeSummary

Exelixis reported strong Q1 2026 financial results with double-digit revenue and EPS growth, authorized a new $750 million share repurchase program, and announced FDA acceptance of its zanzalintinib NDA.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Total revenues increased 10% year-over-year to $610.8 million, driven by an 8% rise in net product revenues from CABOMETYX and a 32% increase in collaboration revenues. Net income grew 32% to $210.5 million, resulting in diluted EPS of $0.79, up 43.6% from $0.55 in Q1 2025.

• New $750 Million Share Repurchase Program

  The Board of Directors authorized an additional $750.0 million stock repurchase program, extending through December 31, 2027. This follows the near completion of a previous $750.0 million program, with $590.6 million repurchased as of March 31, 2026.

• Zanzalintinib NDA Accepted by FDA

  The FDA accepted the New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer, assigning a standard review with a PDUFA target action date of December 3, 2026.

• Pipeline Expansion and Milestones

  Exelixis initiated a Phase 2 trial for zanzalintinib in meningioma (STELLAR-201) and announced planned Phase 2 studies in NSCLC (STELLAR-202) and metastatic castration-resistant prostate cancer (STELLAR-002 expansion). The company also recognized a $7.7 million revenue from an $8.0 million commercial milestone payment from Takeda for cabozantinib sales in Japan.

auto_awesomeAnalysis

Exelixis delivered robust first-quarter 2026 financial results, exceeding prior year performance with significant growth in both total revenues and net income. The company's strategic capital allocation is highlighted by the authorization of an additional $750 million stock repurchase program, signaling confidence in its financial strength and commitment to shareholder returns. Furthermore, the FDA's acceptance of the New Drug Application for zanzalintinib marks a critical regulatory milestone for a key pipeline asset, with a PDUFA target action date set for December 2026. While ongoing patent litigation for CABOMETYX presents a long-term risk, the strong operational performance and pipeline advancements provide a positive outlook.